BioCentury
ARTICLE | Clinical News

Dyax surges on DX-2930 news

April 1, 2015 1:34 AM UTC

Dyax Corp. (NASDAQ:DYAX) jumped $8.40 (50%) to $25.15 in early after-hours trading on Tuesday on postmarket news that its DX-2930 significantly reduced hereditary angioedema (HAE) attacks in a Phase Ib trial. The company, which also said the molecule received Fast Track designation from FDA, plans to meet with the agency to discuss the "minimum pathway forward" for DX-2930 to prevent HAE attacks.

"I don't see a lot of value for doing a Phase II study in preparation for doing a final study for approval," EVP of R&D and CMO Burt Adelman said on a conference call to discuss the data. ...